ATM and neoplasm: We hypothesized that relapse is partly due to Ra-223–induced activation of DNA damage-response pathways; therefore, inhibiting DNA repair pathways with ATM inhibitors (ATMi), currently in clinical trials for other cancers, would radiosensitize bone metastases, increasing anti-tumor efficacy of Ra-223.